RCM
GBT

RA Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

RA Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-457,142
Closed -$14.8M – 43
2015
Q4 		$14.8M Hold
457,142
– – 1.46% 22
2015
Q3 		$19.3M Buy
+457,142
New +$21.6M 2.77% 14

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

RA Capital Management's GBT Position: Q1 2016 in Review

RA Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2016, closing a stake of 457,142 shares — an estimated $14.8M sold.

RA Capital Management first reported a position in GBT in Q3 2015 and held it in 2 quarters. The position peaked at $19.3M in Q3 2015. 75 funds tracked by Wall St. Rank hold GBT as of Q1 2016.

  • RA Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • RA Capital Management sold 457,142 Global Blood Therapeutics, Inc. shares in Q1 2016, an estimated $14.8M.
  • RA Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
  • RA Capital Management's Global Blood Therapeutics, Inc. position peaked at $19.3M in Q3 2015.
  • 75 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2016.

Based on RA Capital Management's 13F filing for Q1 2016, filed 16 May 2016.